Probiotic Yeast Inhibits VEGFR Signaling and Angiogenesis in Intestinal Inflammation

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Chen, Xinhua ^a   Yang, Guoxun ^a   Song, Joo Hye ^b   Xu, Hua ^a   Li, Dan ^a   Goldsmith, Jeffrey ^a   Zeng, Huiyan ^a   Parsons Wingerter, Patricia A ^c   Reinecker, Hans Christian ^b   Kelly, Ciaran P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NASA GLENN RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DOCUSATE SODIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA; PROBIOTIC AGENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CAPILLARY DENSITY; CAPILLARY TUBE; COLITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; LAMINA PROPRIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SACCHAROMYCES BOULARDII; SIGNAL TRANSDUCTION; TISSUE REPAIR; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALS; COLITIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; INFLAMMATION; INTESTINES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROBIOTICS; SACCHAROMYCES; SIGNAL TRANSDUCTION; SODIUM DODECYL SULFATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84877662072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064227     Document Type: Article

References (48)

1. Chen X, Kelly CP (2008) Saccharomyces species. James Versalovic and Michael Wilson editors Therapeutic Microbiology: Probiotics and Other Strategies. Washington DC: American Society of Microbiology. 51-60.
2. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C, (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67: 302-307.
3. Czerucka D, Rampal P, (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4: 733-739.
4. Rodrigues ACP, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR, (1996) Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. Journal of Applied Bacteriology 81: 251-256.
5. Mumy KL, Chen X, Kelly CP, McCormick BA, (2008) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294: G599-609.
6. Brandao RL, Castro IM, Bambirra EA, Amaral SC, Fietto LG, et al. (1998) Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Applied and Environmental Microbiology 64: 564-568.
7. Dias RS, Bambirra EA, Silva ME, Nicoli JR, (1995) Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res 28: 323-325.
8. Sullivan A, Nord CE, (2002) The place of probiotics in human intestinal infections. Int J Antimicrob Agents 20: 313-319.
9. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, et al. (1989) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96: 981-988.
10. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, et al. (2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 1012-1017.
11. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. Jama 271: 1913-1918.
12. McFarland LV, (2007) Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 5: 97-105.
13. McFarland LV, (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812-822.
14. Guslandi M, Mezzi G, Sorghi M, Testoni PA, (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45: 1462-1464.
15. Guslandi M, Giollo P, Testoni PA, (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15: 697-698.
16. Guslandi M Efficacy of a symbiotic product during clinical relapse of ulcerative colitis. J Clin Gastroenterol 45: 475-476.
17. Guslandi M Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol 44: 385.
18. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
19. Folkman J, (2006) Angiogenesis. Annu Rev Med 57: 1-18.
20. Folkman J, (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
21. Dvorak HF, (2005) Angiogenesis: update 2005. J Thromb Haemost 3: 1835-1842.
22. Chidlow JH Jr, Langston W, Greer JJ, Ostanin D, Abdelbaqi M, et al. (2006) Differential angiogenic regulation of experimental colitis. Am J Pathol 169: 2014-2030.
23. Chidlow Jr JH, Shukla D, Grisham MB, Kevil CG, (2007) Pathogenic Angiogenesis in IBD and Experimental Colitis: New Ideas and Therapeutic Avenues. Am J Physiol Gastrointest Liver Physiol Jul 293: G5-G18.
24. Danese S, (2008) Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight. Pathobiology 75: 22-24.
25. Danese S, Sans M, Spencer DM, Beck I, Donate F, et al. (2007) Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 56: 855-862.
26. Hatoum OA, Binion DG, (2005) The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 11: 304-313.
27. Sandor Z, Deng XM, Khomenko T, Tarnawski AS, Szabo S, (2006) Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun 350: 147-150.
28. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, et al. (2009) VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 136: 585-595 e585.
29. Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, et al. (2008) Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 26: 149-155.
30. Sitohy B, Nagy JA, Dvorak HF Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72: 1909-1914.
31. Kroll J, Waltenberger J, (1997) The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272: 32521-32527.
32. Dougher-Vermazen M, Hulmes JD, Bohlen P, Terman BI, (1994) Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 205: 728-738.
33. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, et al. (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281: 24449-24454.
34. Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, et al. (2009) Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology 137: 914-923.
35. Nagy JA, Shih SC, Wong WH, Dvorak AM, Dvorak HF, (2008) Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay. Methods Enzymol 444: 43-64.
36. Parsons-Wingerter P, Radhakrishnan K, Vickerman MB, Kaiser PK Oscillation of angiogenesis with vascular dropout in diabetic retinopathy by VESsel GENeration analysis (VESGEN). Invest Ophthalmol Vis Sci 51: 498-507.
37. Vickerman MB, Keith PA, McKay TL, Gedeon DJ, Watanabe M, et al. (2009) VESGEN 2D: automated, user-interactive software for quantification and mapping of angiogenic and lymphangiogenic trees and networks. Anat Rec (Hoboken) 292: 320-332.
38. Rhee SH, Im E, Riegler M, Kokkotou E, O'Brien M, et al. (2005) Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci U S A 102: 13610-13615.
39. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, et al. (2001) VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 96: 822-828.
40. Tsiolakidou G, Koutroubakis IE, Tzardi M, Kouroumalis EA, (2008) Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. Dig Liver Dis 40: 673-679.
41. Kapsoritakis A, Sfiridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, et al. (2003) Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 18: 418-422.
42. Im E, Choi YJ, Kim CH, Fiocchi C, Pothoulakis C, et al. (2009) The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol Gastrointest Liver Physiol 297: G999-G1008.
43. Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, et al. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104: 1108-1115.
44. Buts JP, Bernasconi P, Vaerman JP, Dive C, (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases And Sciences 35: 251-256.
45. Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, et al. (2001) Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infection And Immunity 69: 2762-2765.
46. Rodrigues AC, Cara DC, Fretez SH, Cunha FQ, Vieira EC, et al. (2000) Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89: 404-414.
47. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, et al. (2006) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131: 1812-1825.
48. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, et al. (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343: 69-76.